Literature DB >> 9177467

Role of perforin, granzymes and the proliferative state of the target cells in apoptosis and necrosis mediated by bispecific-antibody-activated cytotoxic T cells.

C Renner1, G Held, S Ohnesorge, S Bauer, K Gerlach, J P Pfitzenmeier, M Pfreundschuh.   

Abstract

Bispecific monoclonal antibodies (bi-mAb), directed against a tumor-associated antigen and the CD3 or CD28 antigen on T lymphocytes, induce activation of resting T lymphocytes and target-specific tumor cell lysis. We now show that both necrosis and apoptosis contribute to T-cell-mediated tumor cell destruction. Even though T cells up-regulate FAS/APO-1 expression upon bi-mAb stimulation, FAS/APO-1-mediated apoptosis does not contribute to bi-mAb-mediated destruction of Hodgkin's cells. CD8+ lymphocytes were the most potent effectors of bi-mAb-mediated cytotoxicity and had the highest levels of mRNA coding for perforin and granzyme A and B. Ca2+-complexing agents, which abrogate perforin activity, led to decreased levels of necrosis, while inhibition of granzyme activity in effector or target cells had a similar effect on apoptosis. Granzyme-mediated apoptosis critically dependent on the proliferative state of the target cells, while perforin-induced necrosis was not cell-cycle-dependent. Our results underline the importance of the expression levels of perforin and granzymes in the effector T cells and of the proliferative state of the target cells in bi-mAb-mediated apoptosis and necrosis of tumor cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9177467     DOI: 10.1007/s002620050357

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  5 in total

Review 1.  Targeting T cells with bispecific antibodies for cancer therapy.

Authors:  Lawrence G Lum; Archana Thakur
Journal:  BioDrugs       Date:  2011-12-01       Impact factor: 5.807

2.  Identification of an apoptosis-related prognostic gene signature and molecular subtypes of clear cell renal cell carcinoma (ccRCC).

Authors:  Weimin Zhong; Fengling Zhang; Chaoqun Huang; Yao Lin; Jiyi Huang
Journal:  J Cancer       Date:  2021-04-02       Impact factor: 4.207

3.  A combined nucleocapsid vaccine induces vigorous SARS-CD8+ T-cell immune responses.

Authors:  Ali Azizi; Susan Aucoin; Helina Tadesse; Rita Frost; Masoud Ghorbani; Catalina Soare; Turaya Naas; Francisco Diaz-Mitoma
Journal:  Genet Vaccines Ther       Date:  2005-08-22

4.  TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL.

Authors:  Harbani K Malik-Chaudhry; Kirthana Prabhakar; Harshad S Ugamraj; Andrew A Boudreau; Benjamin Buelow; Kevin Dang; Laura M Davison; Katherine E Harris; Brett Jorgensen; Heather Ogana; Duy Pham; Ute Schellenberger; Wim Van Schooten; Roland Buelow; Suhasini Iyer; Nathan D Trinklein; Udaya S Rangaswamy
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

5.  B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.

Authors:  Juan Ma; Pan Ma; Chenghai Zhao; Xin Xue; Huamin Han; Changzhen Liu; Hua Tao; Weigang Xiu; Jia Cai; Man Zhang
Journal:  Oncotarget       Date:  2016-05-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.